Andrea Chen joined COUR in 2025 as Head of Program Management, overseeing the strategic planning, coordination, and execution of development activities across all programs.
With over 15 years of experience in product development, drug manufacturing, drug development, transformation initiatives, and program management, Andrea has led teams through every stage of the pharmaceutical development process. She has supported the advancement of pre-clinical, clinical and commercial-stage assets, with expertise spanning operational excellence, biotechnology, and cross-functional leadership.
Before joining COUR, Andrea was Senior Director of Global Program Management at Amgen, leading commercialization strategy and cross-functional program execution in rare disease, specifically focused on TEPEZZA and the Thyroid Eye Disease franchise. Prior to Amgen, she held leadership roles at Horizon Therapeutics from 2021 to 2023, and spent over nine years at AbbVie, progressing through project and program management roles supporting clinical and supply operations, company integrations, enterprise system and process implementations and center of excellence teams. Earlier in her career, Andrea gained broad experience in clinical research, in-vivo testing and supply management through positions at Abbott, Children’s Memorial Hospital, and Kimberly-Clark.
Andrea holds a Bachelor of Science in Biology and a Master of Science in Nutritional Sciences, both from the University of Wisconsin–Madison, where she conducted research on bone health and atherosclerosis in hypercholesterolemic pig models. She is passionate about building collaborative teams, mentoring young women in STEM fields, and bringing life-changing therapies to patients through collaborative and strategic leadership.